The Lab Emergency After Treatment Starts: Tumour Lysis Syndrome
Most cancer complications arrive because the disease is winning. This one arrives because the drug is working. A treatment hits a large, fast-dividing tumour, enormous numbers of cells break open at once, and everything meant to stay inside them floods into the blood. The person in the bed can still look and feel much the same. The blood panel does not. Tumour lysis syndrome shows up in four numbers before it shows up in the patient, and holding those four as one moving picture instead of four separate results is exactly what Healz's memory is for.
This post walks the complication from the inside: what spills out of a dying cancer cell, what each of the four values does, why the kidneys take the damage, who sits in the risk group, and what the treating team watches in the days after the first dose. This is inpatient medicine, run with scheduled bloods and a cardiac monitor, written out so the words on the chart make sense.

Why the danger starts when the treatment works
A cancer cell is a bag of concentrated chemistry. Inside it, potassium sits at far higher levels than in the bloodstream, phosphate is stockpiled for building new cells, and the nucleus is packed with nucleic acids. While the cell is intact, none of that reaches the circulation. When treatment kills a very large number of those cells inside a few hours, all of it arrives at once, faster than the kidneys can clear it.
The nucleic acids are the part that surprises people. They are broken down into purines and then into uric acid, the body's normal waste product from dying cells. MedlinePlus puts it directly: "When treatment kills cancer cells quickly, they release large amounts of purines into the blood." The NCI describes the resulting condition as one that can follow treatment of fast-growing cancers, especially certain leukaemias and lymphomas, where the contents of dying tumour cells change blood chemistry and can damage the kidneys and the heart.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
It does not always wait for a drug. The syndrome occurs "either spontaneously or in response to therapy" (Howard and colleagues, New England Journal of Medicine, 2011). Spontaneous cases, where the tumour turns over fast enough to do this before anything is given, occur in blood cancers and, more rarely, solid tumours.
The four numbers, and what each one does
The four values are not an arbitrary panel. Each is an intracellular substance arriving in the wrong compartment.
Potassium. Per MedlinePlus, "your cells, nerves, heart, and muscles need potassium to work properly," and it lists arrhythmia, a problem with the heart's rate or rhythm, among the effects of a high level. This is the value that turns dangerous fastest, which is why high-risk patients go on continuous cardiac monitoring.
Phosphate. Released from the same cells and cleared by the same kidneys. Its second effect matters as much as its first: high phosphate can cause secondary low calcium (Howard, New England Journal of Medicine, 2011), which is why the fourth number moves the other way.
Uric acid. The end product of all those nucleic acids. MedlinePlus notes that when the kidneys cannot remove enough of it, "high uric acid levels can also cause kidney stones, or kidney failure."
Calcium, falling. MedlinePlus describes blood calcium as "necessary for your nerves, muscles, and heart to work properly," and a low level as producing muscle cramps or stiffness, tingling in the lips and fingers, irregular heartbeat, and seizures when it drops far enough. Three numbers climbing and one dropping is the shape of the diagnosis.
Why the kidneys end up carrying it
The kidney is where the chemistry turns into organ damage, by more than one route. Calcium phosphate, uric acid and xanthine can all precipitate in the renal tubules, and uric acid also injures it through mechanisms that involve no crystals (Howard, New England Journal of Medicine, 2011).
That damage is what turns laboratory tumour lysis syndrome into clinical tumour lysis syndrome. Acute kidney injury here means a creatinine rise of at least 0.3 mg/dl, or urine output below 0.5 ml/kg/hr for six hours; where no baseline creatinine exists, a single value above 1.5 times the age-appropriate upper limit counts instead.
Who the treating team watches hardest
The syndrome "develops most often in patients with non-Hodgkin's lymphoma or acute leukemia" (Howard, New England Journal of Medicine, 2011), and bulky Burkitt lymphoma is singled out as carrying a high potential for lysis. Our piece on the B symptoms that bring someone in with lymphoma covers how that diagnosis announces itself; this post picks up where treatment is about to start.
Risk is not read off the diagnosis alone. It rises with bulky disease, organ infiltration, bone marrow involvement, a lactate dehydrogenase above twice the upper normal limit, a tumour that is highly chemosensitive, and intensive initial therapy. The protocol matters as much as the cancer: an acute lymphoblastic leukaemia regimen opening with a multidrug combination carries more risk than one opening with prednisone alone.
The scale shows up in the opening blood count: the child in Howard's case report presented with a white-cell count of 84,600 per cubic millimetre. How such a count is read before any of this begins is the subject of our guide on reactive versus malignant blood counts.
It is not only classical chemotherapy. Venetoclax, used in chronic lymphocytic leukaemia, is given as a stepwise ramp-up from 20 mg to 400 mg over roughly five weeks, designed to reduce tumour burden gradually and lower the risk, and laboratory changes can occur within hours of starting (Anderson and colleagues, Cancers, 2024). A drug that needs a five-week run-up is a drug that works.
Laboratory or clinical: why the chart carries two labels
The vocabulary comes from the Cairo-Bishop classification (British Journal of Haematology, 2004), which split the syndrome into two tiers still in use today.
Laboratory tumour lysis syndrome means two or more of the four abnormalities present in the same 24-hour period, within three days before the start of therapy or up to seven days afterwards. The adult thresholds are uric acid above 8.0 mg/dl, phosphorus above 4.5 mg/dl, potassium above 6.0 mmol/litre, and corrected calcium below 7.0 mg/dl (Howard, New England Journal of Medicine, 2011). Children carry a higher phosphorus cutoff, above 6.5 mg/dl. Cairo-Bishop also allowed a 25% change from baseline, so the definition can be met without any value crossing those thresholds; Howard and colleagues propose dropping that one.
Clinical tumour lysis syndrome is that same chemistry plus a consequence: a rise in creatinine, a seizure, a cardiac dysrhythmia, or death. One label describes a blood result that was caught and is being corrected. The other describes an organ that has already been hit. Howard and colleagues have argued for tightening it further: the two abnormalities present at the same time rather than anywhere in the window, and any symptomatic low calcium counted as clinical disease.
What the team puts in place before the first dose
Prevention is the whole game here, and it starts before treatment, not after the first bad result.
Intravenous hydration comes first for everyone at risk, to keep the kidneys perfused and urine flowing, at roughly 2,500 to 3,000 ml per square metre per day in the highest-risk patients, with a loop diuretic added if output stays low against a target of at least 2 ml/kg/hr (Howard, New England Journal of Medicine, 2011). Then the uric acid is handled. Allopurinol works by inhibiting xanthine oxidase, which stops new uric acid forming but does nothing about what is already there, and it can lead to xanthine building up instead. Rasburicase is a recombinant urate oxidase that converts uric acid into allantoin, which is far more soluble, and it is "recommended as first-line treatment for patients who are at high risk" of clinical disease. It is contraindicated in G6PD deficiency. Low-risk patients are generally managed with fluids, with or without allopurinol.
The watching window is the other half. In the highest-risk group, electrolytes, creatinine and uric acid are checked every four to six hours after therapy starts, alongside continuous cardiac monitoring; intermediate risk is every eight to twelve hours, and low risk is daily. The window does not close on day one: in one acute lymphoblastic leukaemia induction protocol, new cases appeared as late as day six or seven. For a venetoclax start, chemistry is checked around the first dose at each new level, with one published schedule at six to eight hours and twenty-four hours after the first dose (Anderson and colleagues, Cancers, 2024).
How Healz reads four values across the days after treatment starts
Tumour lysis syndrome is not a result, it is a slope on four lines at once, and those lines usually arrive as separate pages: a panel from last night, one from this morning, a creatinine on a different printout. Healz is equipped with memory, and it does three things by design: it pulls the medical facts out of every panel you upload, dates each one, and keeps the abnormal values up front, so potassium, phosphate, uric acid and calcium are read against their own history and against each other, not one page at a time.
The rest of the case lives in the same chat. As a blood test ai analyzer, Healz is equipped to read the full chemistry panel beside the pathology report and the treatment record, so a rising phosphate is read next to the falling calcium that follows it. Frontier AI works the whole file. Root-cause technology asks what a rushed conversation skips and cross-checks the case against more than a million rare cases, so a pattern is traced back to its cause rather than stopped at the first label. This is the cancer ai and ai oncology work that normally takes four portals and a paper folder: everything in one place, one chat, not ten apps. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What is tumour lysis syndrome in simple terms?
It is what happens when a very large number of cancer cells die at nearly the same time and their contents spill into the blood faster than the kidneys can clear them. Potassium, phosphate and uric acid rise, calcium falls, and the kidneys are the organ most likely to be injured (NCI; Howard, New England Journal of Medicine, 2011). It is managed in hospital with fluids, uric acid drugs and frequent blood tests.
- What are the four lab values in tumour lysis syndrome?
Potassium, phosphate and uric acid go up, and calcium goes down. Laboratory tumour lysis syndrome needs two or more of those abnormalities in the same 24-hour window, within three days before treatment or up to seven days after it starts (Howard, New England Journal of Medicine, 2011). The calcium falls largely because the rising phosphate drives it down.
- Which cancers have the highest risk of tumour lysis syndrome?
It occurs most often with non-Hodgkin's lymphoma or acute leukaemia, and bulky Burkitt lymphoma is described as carrying a high potential for lysis (Howard, New England Journal of Medicine, 2011). Risk also tracks with bulky disease, marrow involvement, a high lactate dehydrogenase, and an intensive opening regimen.
- Does tumour lysis syndrome mean the chemotherapy is working?
In one sense it is evidence the treatment is killing cancer cells, and the highest risk sits with the tumours that respond fastest. It is still a serious complication rather than good news, which is why prevention runs before the first dose and the bloods are drawn on a schedule.
The cruel arithmetic of this one is that the better the drug works, the more chemistry it releases. What keeps that survivable is nothing dramatic: four values, drawn often enough, read together across days rather than one panel at a time.
Written by Healz Team · Filed under Health Insights